SHORT COMMUNICATION

Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation. Sophie E. Rowbotham, Alan V. Boddy, Chris P. F. Redfern, Gareth J. Veal, and Ann K. Daly. ......................................................... 1261

ARTICLES

Formation Pathways of γ-Butyrolactone from the Furan Ring of Tegafur during Its Conversion to 5-Fluorouracil. Ikuo Yamamiya, Kunihiro Yoshisue, Eiji Matsushima, and Sekio Nagayama .......... 1267

Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications. Sharon Diamond, Jason Boer, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh, Yu Li, and Swamy Yeleswaram ................... 1277


Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies. Upendra A. Argikar, Javier Gomez, Din Ung, Henry P. Parkman, and Swati Nagar .......................... 1295

Methadone: A Substrate and Mechanism-Based Inhibitor of CYP19 (Aromatase). Wenjie Jessie Lu, Robert Bies, Landry K. Kamen, Zerusenay Desta, and David A. Flockhart ............ 1308


In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase. Michael Zientek, Ying Jiang, Kuresh Youdin, and R. Scott Obach ........................... 1322

Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients. Aishen Gong, Xiaoyan Chen, Pan Deng, and Dafang Zhong ............. 1328

In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein. M. J. Gnoth, S. Sandmann, K. Engel, and M. Radtke ...................... 1341


Central Nervous System Penetration for Small Molecule Therapeutic Agents Does Not Increase in Multiple Sclerosis- and Alzheimer’s Disease-Related Animal Models Despite Reported Blood-Brain Barrier Disruption. Ziqiang Cheng, Jingqiang Zhang, Houfu Liu, Yi Li, Yonggang Zhao, and Eric Yang ........................................... 1355


In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase. Michael Zientek, Ying Jiang, Kuresh Youdin, and R. Scott Obach ........................... 1322

Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients. Aishen Gong, Xiaoyan Chen, Pan Deng, and Dafang Zhong ............. 1328

In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein. M. J. Gnoth, S. Sandmann, K. Engel, and M. Radtke ...................... 1341


Central Nervous System Penetration for Small Molecule Therapeutic Agents Does Not Increase in Multiple Sclerosis- and Alzheimer’s Disease-Related Animal Models Despite Reported Blood-Brain Barrier Disruption. Ziqiang Cheng, Jingqiang Zhang, Houfu Liu, Yi Li, Yonggang Zhao, and Eric Yang ........................................... 1355


In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase. Michael Zientek, Ying Jiang, Kuresh Youdin, and R. Scott Obach ........................... 1322

Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients. Aishen Gong, Xiaoyan Chen, Pan Deng, and Dafang Zhong ............. 1328

In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein. M. J. Gnoth, S. Sandmann, K. Engel, and M. Radtke ...................... 1341


Central Nervous System Penetration for Small Molecule Therapeutic Agents Does Not Increase in Multiple Sclerosis- and Alzheimer’s Disease-Related Animal Models Despite Reported Blood-Brain Barrier Disruption. Ziqiang Cheng, Jingqiang Zhang, Houfu Liu, Yi Li, Yonggang Zhao, and Eric Yang ........................................... 1355


In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase. Michael Zientek, Ying Jiang, Kuresh Youdin, and R. Scott Obach ........................... 1322

Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients. Aishen Gong, Xiaoyan Chen, Pan Deng, and Dafang Zhong ............. 1328

In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein. M. J. Gnoth, S. Sandmann, K. Engel, and M. Radtke ...................... 1341


Central Nervous System Penetration for Small Molecule Therapeutic Agents Does Not Increase in Multiple Sclerosis- and Alzheimer’s Disease-Related Animal Models Despite Reported Blood-Brain Barrier Disruption. Ziqiang Cheng, Jingqiang Zhang, Houfu Liu, Yi Li, Yonggang Zhao, and Eric Yang ........................................... 1355

In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters. Makiko Kusama, Kouta Toshimoto,
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib. Marius Dohse, Christian Scharenberg, Suneet Shukla, Robert W. Robey, Thorsten Volkmann, John F. Deeken, Cornelia Brendel, Suresh V. Ambudkar, Andreas Neubauer, and Susan E. Bates

Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics. R. Scott Obach and Tim F. Ryder

About the cover: Distribution of drugs in the three-dimensional area and the rectangular boundaries for each pathway. See the article by Kusama et al. on page 1362 of this issue.